Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma

Walter Hanel, MD, Beth A. Christian, MD, Kami J. Maddocks, MD, Narendranath Epperla, MDMS, Basem M. William, MDMRCP, Samantha Jaglowski, MD MPH, David A. Bond, MD, Yazeed Sawalha, MD, John C. Reneau, MDPhD, Jonathan E Brammer, MD, Robert Baiocchi, MD PhD, Kristie A. Blum, MD, Lapo Alinari, MD PhD

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-141243

Published: 2020

Journal Articles

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

Fiona Brown, BS, Yang Zhang, PhD, Claire Hinterschied, Alexander Prouty, BS, Shelby Sloan, BS, JoBeth Helmig-Mason, Msc, Ji Hyun Chung, PhD, Kris Vaddi, PhD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Lapo Alinari, MD PhD, Peggy Scherle, PhD, Rosa Lapalombella, PhD, Jihye Paik, PhD, Robert A Baiocchi, MD PhD

Blood (2019) 134 (Supplement_1): 302.

https://doi.org/10.1182/blood-2019-130797

Published: 2019

Journal Articles

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

David A. Bond, MD, Vedat Yildiz, Lai Wei, PhD, Lapo Alinari, MD PhD, Basem M. William, MRCP,MD, Jonathan E. Brammer, MD, Beth A. Christian, MD, Kristie A. Blum, MD, Kami J. Maddocks, MD

Blood (2019) 134 (Supplement_1): 4091.

https://doi.org/10.1182/blood-2019-130539

Published: 2019

Journal Articles

Targeting Hypersumoylation in Mantle Cell Lymphoma

Walter Hanel, MD PhD, Liudmyla Tsyba, PhD, Dennis Huszar, PhD, Alex Prouty, Xiaoli Zhang, PhD, JoBeth Helmig-Mason, Msc, Bethany L Mundy-Bosse, PhD, Youssef Youssef, MD, Samir Parekh, MD, Kami J. Maddocks, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD

Blood (2019) 134 (Supplement_1): 4060.

https://doi.org/10.1182/blood-2019-127363

Published: 2019

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Shelby Sloan, BS, Fiona Brown, BS, JI Hyun Chung, PhD, Alexander Prouty, BS, Esther Wheeler, BS, Bonnie K Harrington, DVM, PhD, Eric Brooks, BS, Ayse S Yilmaz, MS, Hatice G Ozer, PhD, John C. Byrd, MD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Rosa Lapalombella, PhD, Kris Vaddi, PhD, Peggy Scherle, PhD, Youssef Youssef, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD

Blood (2019) 134 (Supplement_1): 4065.

https://doi.org/10.1182/blood-2019-128998

Published: 2019

Journal Articles

PRMT5 Initiates an Epigenetic Program That Promotes Progression of Chronic Lymphocytic Leukemia

Zachary A Hing, BS, Jordan N. Skinner, B.S., Larry P. Beaver, Tzung-Huei Lai, PhD, Casey B. Cempre, B.S., Bonnie K. Harrington, DVM, Deepa Sampath, PhD, Amy M. Lehman, PhD, Lianbo Yu, PhD, Lapo Alinari, MD PhD, John C. Byrd, MD, Robert A Baiocchi, MD PhD, Rosa Lapalombella, PhD

Blood (2017) 130 (Supplement 1): 2487.

https://doi.org/10.1182/blood.V130.Suppl_1.2487.2487

Published: 2017

Journal Articles

PRMT5 Transgenic Mice Develop Aggressive Lymphoblastic Lymphomas

Porsha L. Smith, PhD, Fengting Yan, MD PhD, John T. Patton, PhD, Lapo Alinari, MD PhD, Vrajesh Karkhanis, PhD, Leona Ayers, MD, Natarajan Muthusamy, DVM, PhD, Anjali Mishra, PhD, Elshafa Ahmed, DVM, Said Sif, PhD, Rosa Lapalombella, PhD, Robert A Baiocchi, MD PhD

Blood (2016) 128 (22): 2936.

https://doi.org/10.1182/blood.V128.22.2936.2936

Published: 2016

Journal Articles

PRMT5 Targets Tumor Suppressor Micro RNAs to Regulate Cyclin D1 and c-MYC in Mantle Cell Lymphoma

Vrajesh Karkhanis, PhD, Lapo Alinari, MD PhD, Bethany Mundy, MD, Michael Caliguri, MD, Selina Chen-Kiang, PhD, Olivier Elemento, PhD, Sif Said, PhD, Robert A Baiocchi, MD PhD

Blood (2016) 128 (22): 2937.

https://doi.org/10.1182/blood.V128.22.2937.2937

Published: 2016

Journal Articles

Poor Prognostic Effect of CD5 Positivity for Patients with Diffuse Large B-Cell Lymphoma: Results from a Retrospective Single Institution Analysis

Lapo Alinari, MD PhD, Alejandro Gru, MD, Carl Quinion, Ying Huang, PhD, Jeffrey A. Jones, MD, Steven M. Devine, MD, Kami J. Maddocks, MD, Beth Christian, MD, Robert A. Baiocchi, MD PhD, Kristie A. Blum, MD

Blood (2014) 124 (21): 1700.

https://doi.org/10.1182/blood.V124.21.1700.1700

Published: 2014

Journal Articles

Protein Arginine Methyltransferase 5 (PRMT5) Over-Expression Is Essential for Epstein-Barr Virus-Driven B-Cell Transformation.

Lapo Alinari, MD., Ph.D., Fengting Yan, M.D., Ph.D., Porsha Smith, John T. Patton, Carl Quinion, Bo Yu, Ph.D, Christian Tyler Earl, Mark E Lustberg, MD, PhD, Lynda Villagomez, Erin K Hertlein, PhD, John C. Byrd, MD, Leona Ayers, MD, Tasneem Motiwala, PhD, Sarmila Majumder, PhD, Chenglong Li, Ph.D., Said Sif, Ph.D., Samson T. Jacob, PhD, Robert A. Baiocchi, M.D., Ph.D.

Blood (2012) 120 (21): 2378.

https://doi.org/10.1182/blood.V120.21.2378.2378

Published: 2012

Journal Articles

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

Beth Christian, MD, Lapo Alinari, MD., Ph.D., Jeffrey A. Jones, MD, MPH, Don M Benson, Jr., MD, PhD, Joseph M. Flynn, DO, MPH, Pierluigi Porcu, MD, Mark E Lustberg, MD, PhD, Mitchell Phelps, Ph.D., Ming Poi, PharmD, PhD, Diana Chung, BS, Carl Quinion, John C. Byrd, MD, William Wegener, MD, PhD, David M Goldenberg, Robert A. Baiocchi, M.D., Ph.D., Kristie A. Blum, MD

Blood (2011) 118 (21): 3707.

https://doi.org/10.1182/blood.V118.21.3707.3707

Published: 2011

Journal Articles

Targeting the Cyclin D - CDK4/6 - Rb Axis in Mantle Cell Lymphoma with the Novel Translation Inhibitor Silvestrol,

Lapo Alinari, MD., Ph.D., Ryan B. Edwards, Courtney J. Prince, William H. Towns, Rajeswaran Mani, DVM, Amy Lehman, Xiaoli Zhang, PhD, MS, David Jarjoura, PhD, Li Pan, PhD, A. Douglas Kinghorn, PhD, DSc, Michael R. Grever, M.D., Robert A. Baiocchi, M.D., Ph.D., David M. Lucas, PhD

Blood (2011) 118 (21): 3498.

https://doi.org/10.1182/blood.V118.21.3498.3498

Published: 2011

Journal Articles

Developing a Novel Class of Drug to Inhibit Protein Arginine Methyltransferase 5 (PRMT5) Enzyme Dysregulation in Mantle Cell Lymphoma

Fengting Yan, M.D., Ph.D., Porsha Smith, Lapo Alinari, MD., Ph.D., John Ryu, Bo Yu, Ph.D., Vrajesh Karkhanis, Ph.D., Sookil Tae, Ph.D., John T. Patton, Emily E. Wilding, Kate Gordon, Kiran Mahasenan, Ph.D., Deepak Bhasin, Ph.D., Claudio Agostinelli, M.D., Ph.D., Stefano A. Pileri, M.D., John C. Byrd, MD, Said Sif, Ph.D., Pui-kai Li, Ph.D., Chenglong Li, Ph.D., Robert A. Baiocchi, M.D., Ph.D.

Blood (2011) 118 (21): 595.

https://doi.org/10.1182/blood.V118.21.595.595

Published: 2011

Journal Articles

FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death

Lapo Alinari, MD., Ph.D., Emilia Mahoney, MD, PhD, John T. Patton, Xiaoli Zhang, PhD, MS, Lenguyen Huynh, Christian Tyler Earl, Rajeswaran Mani, DVM, Yicheng Mao, Bo Yu, Ph.D., William H. Towns, Ching-Shih Chen, Ph.D, David M. Goldenberg, Kristie A. Blum, MD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D, Mette Ibba, PhD, Robert A. Baiocchi, M.D., Ph.D.

Blood (2011) 118 (21): 600.

https://doi.org/10.1182/blood.V118.21.600.600

Published: 2011

Journal Articles

A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma.

Beth Christian, MD, Lapo Alinari, MD, Christian Tyler Earl, Emily Wilding, Carl Quinion, Mark Lustberg, MD, PhD, Don M Benson, Jr., MD, PhD, Jeffrey A. Jones, MD, MPH, John C. Byrd, MD, William A. Wegener, MD, PhD, David M. Goldenberg, ScD, MD, Robert A. Baiocchi, MD, PhD, Kristie A. Blum, MD

Blood (2010) 116 (21): 2788.

https://doi.org/10.1182/blood.V116.21.2788.2788

Published: 2010

Journal Articles

Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-Kb.

Lapo Alinari, MD, Beth Christian, MD, Bo Yu, Jungook Shin, Erin K Hertlein, PhD, Rosa Lapalombella, PhD, Fengting Yan, MD, PhD, Gregory Lesinski, PhD, Xiaoli Zhang, PhD, Gerard Lozanski, MD, Natarajan Muthusamy, PhD, David M. Goldenberg, ScD, MD, John C. Byrd, MD, Robert A. Baiocchi, MD, PhD

Blood (2009) 114 (22): 1694.

https://doi.org/10.1182/blood.V114.22.1694.1694

Published: 2009

Journal Articles

FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.

Lapo Alinari, MD, Qing Liu, PhD, Ching-Shih Chen, PhD, Fengting Yan, MD, PhD, James T Dalton, PhD, Rosa Lapalombella, PhD, Xiaoli Zhang, PhD, Teresa Lin, BS, John C. Byrd, MD, Robert A. Baiocchi, MD, PhD, Natarajan Muthusamy, PhD

Blood (2009) 114 (22): 3728.

https://doi.org/10.1182/blood.V114.22.3728.3728

Published: 2009

Journal Articles

Combination Anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody Therapy Has in Vitro and in Vivo Activity in Mantle Cell Lymphoma

Lapo Alinari, MD, Erin Hertlein, PhD, David M. Goldenberg, ScD, MD, Rosa Lapalombella, PhD, Fengting Yan, MD, PhD, Xiaoli Zhang, PhD, David M. Lucas, PhD, Natarajan Muthusamy, PhD, John C. Byrd, MD, Robert A. Baiocchi, MD, PhD

Blood (2008) 112 (11): 886.

https://doi.org/10.1182/blood.V112.11.886.886

Published: 2008

Journal Articles

FDG-PET in the Serial Assessment of Patients with Lymphoma in Complete Remission.

Pier Luigi Zinzani, MD, PhD, Vittorio Stefoni, MD, Valentina Ambrosini, MD, Enrico Derenzini, MD, Gerardo Musuraca, MD, Enrica Marchi, MD, Lapo Alinari, MD, Mariapaola Fina, MD, Monica Tani, MD, Cinzia Pellegrini, MD, Stefano Fanti, MD, Michele Baccarani, MD

Blood (2007) 110 (11): 216.

https://doi.org/10.1182/blood.V110.11.216.216

Published: 2007

NARROW

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

Targeting Hypersumoylation in Mantle Cell Lymphoma

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

PRMT5 Initiates an Epigenetic Program That Promotes Progression of Chronic Lymphocytic Leukemia

PRMT5 Transgenic Mice Develop Aggressive Lymphoblastic Lymphomas

PRMT5 Targets Tumor Suppressor Micro RNAs to Regulate Cyclin D1 and c-MYC in Mantle Cell Lymphoma

Poor Prognostic Effect of CD5 Positivity for Patients with Diffuse Large B-Cell Lymphoma: Results from a Retrospective Single Institution Analysis

Protein Arginine Methyltransferase 5 (PRMT5) Over-Expression Is Essential for Epstein-Barr Virus-Driven B-Cell Transformation.

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

Targeting the Cyclin D - CDK4/6 - Rb Axis in Mantle Cell Lymphoma with the Novel Translation Inhibitor Silvestrol,

Developing a Novel Class of Drug to Inhibit Protein Arginine Methyltransferase 5 (PRMT5) Enzyme Dysregulation in Mantle Cell Lymphoma

FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death

A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma.

Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-Kb.

FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.

Combination Anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody Therapy Has in Vitro and in Vivo Activity in Mantle Cell Lymphoma

FDG-PET in the Serial Assessment of Patients with Lymphoma in Complete Remission.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only